Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity

Risk concerns related to ocrelizumab treatment for multiple sclerosis (MS) during the COVID-19 pandemic caused infusion delays with extended interval dosing (EID). We reviewed medical records of patients on ocrelizumab to determine whether EID maintains its effectiveness compared to standard interva...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis 2024-02, Vol.30 (2), p.257-260
Main Authors: Bou Rjeily, Nicole, Fitzgerald, Kathryn C, Mowry, Ellen M
Format: Article
Language:English
Subjects:
COVID-19
Dosage
Medical records
Multiple sclerosis
Patients
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Risk concerns related to ocrelizumab treatment for multiple sclerosis (MS) during the COVID-19 pandemic caused infusion delays with extended interval dosing (EID). We reviewed medical records of patients on ocrelizumab to determine whether EID maintains its effectiveness compared to standard interval dosing (SID). Among 361 patients, 231 (64%) and 123 (34%) had at least one infusion with infusion intervals of ⩾8 months and ⩾12 months, respectively. There were no differences in demographics or clinical profiles between the SID and EID groups. No significant differences between rates of breakthrough activity among relapsing-remitting patients were observed between SID (three patients) and EID (seven patients).
ISSN:1352-4585
1477-0970
DOI:10.1177/13524585231208311